早期非小细胞肺癌的体部立体定向放疗

doi:10.3760/cma.j.issn.1673-422X.2015.10.015

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (10): 773-775.doi: 10.3760/cma.j.issn.1673-422X.2015.10.015

早期非小细胞肺癌的体部立体定向放疗

林莉,周福祥

430071 武汉大学中南医院放化疗科国家临床重点专科湖北省肿瘤医学临床研究中心肿瘤生物学行为湖北省重点实验室

出版日期:2015-10-08 发布日期:2015-09-08
通讯作者: 周福祥 E-mail:happyzhoufx@sina.com
基金资助:
湖北省自然科学基金（2013CFA006）

Stereotactic body radiotherapy for early stage nonsmall cell lung cancer

Lin Li, Zhou Fuxiang

Department of Radiation and Chemotherapy, Zhongnan Hospital of Wuhan University, State Key Clinical Specialty, Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behavior, Wuhan 430071, China

Online:2015-10-08 Published:2015-09-08
Contact: Zhou Fuxiang E-mail:happyzhoufx@sina.com

摘要/Abstract

摘要： 作为早期非小细胞肺癌治疗的一种治疗模式，体部立体定向放疗（SBRT）目前主要在非手术患者中应用。相比较传统分次小剂量照射，SBRT采取单次大剂量照射，近年来临床研究主要集中在其有效的生物有效剂量等效换算模型及最佳剂量分割模式的探索，但尚未达成共识。研究表明SBRT相较普通放疗在局部控制率、不良反应等方面具有一定优势，日后可应用于可手术患者。

关键词: 癌, 非小细胞肺, 放射疗法, 体部立体定向放疗

Abstract: As one of the treatment options for early stage NSCLC, stereotactic body radiation therapy (SBRT) is mainly applied to the inoperable patients. Compared with small doses of traditional fractionated radiation treatment, SBRT are taken a single high dose of radiation. A large body of experience has been accumulated over the years and the mathematical model to describe survival in high dose range typically used in SBRT and the best dose of segmentation model were focused on, but there has not yet reached a consensus. Studies show that SBRT has certain advantages in local control ratio and adverse reaction compared with traditional radiotherapy, which can be used in operable patients in the future.

Key words: Carcinoma, non-small-cell lung, Radiotherapy, Stereotactic body radiation therapy

林莉,周福祥. 早期非小细胞肺癌的体部立体定向放疗[J]. 国际肿瘤学杂志, 2015, 42(10): 773-775.

Lin Li, Zhou Fuxiang. Stereotactic body radiotherapy for early stage nonsmall cell lung cancer[J]. Journal of International Oncology, 2015, 42(10): 773-775.

参考文献

［1］李宏奇, 王颖杰, 李平, 等. 体部伽马刀治疗早期非小细胞肺癌临床观察［J］. 中华放射肿瘤杂志, 2012, 21(4): 321-324. ［2］ Fernando HC, Timmerman R. American college of surgeons oncology group Z4099/radiation therapy oncology group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for highrisk stage Ⅰ nonsmall cell lung cancer［J］. Thorac Cardiovasc Surg, 2012, 144(3): S35-S38. ［3］ Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy［J］. Radiat Oncol Biol Phys, 2008, 70(3): 847-852. ［4］ Wang JZ, Huang Z, Lo SS, et al. A generalized linearquadratic model for radiosurgery, stereotactic body radiation therapy, and highdose rate brachytherapy［J］. Sci Transl Med, 2010, 2(39): 39ra48. ［5］ Chi A, Wen S, Liao Z, et al. What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage nonsmall cell lung cancer［J］. Biomed Res Int, 2013, 2013: 391021. ［6］ Senan S, Palma DA, Lagerwaard FJ. Stereotactic ablative radiotherapy for stage Ⅰ NSCLC: recent advances and controversies［J］. J Thorac Dis, 2011, 3(3): 189-196. ［7］ Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage Ⅰ nonsmallcell lung cancer: can SBRT be comparable to surgery?［J］. Int J Radiat Oncol Biol Phys, 2011, 81(5): 1352-1358. ［8］ Stephans K. Stereotactic body radiotherapy for stage Ⅰ nonsmall cell lung cance［J］. Cleve Clin J Med, 2012, 79 Electronic Suppl 1: eS26-S31. ［9］ Onishi H, Araki T. Stereotactic body radiation therapy for stage Ⅰ nonsmallcell lung cancer: a historical overview of clinical studies［J］. Jpn J Clin Oncol, 2013, 43(4): 345-350. ［10］ Videtic GM, Stephans KL, Woody NM, et al. 30 Gy or 34 Gy comparing 2 singlefraction SBRT dose schedules for stage Ⅰ medically inoperable nonsmall cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2014, 90(1): 203-208. ［11］ Mutter RW, Liu F, Abreu A, et al. Dosevolume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1783-1790. ［12］ Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2010, 76(3): 796-801. ［13］ Nagata Y, Wulf J, Lax I, et al. Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency［J］. Int J Radiat Oncol Biol Phys, 2011, 79(3): 660-669. ［14］ Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ nonsmall cell lung cancer: updated results of 257 patients in a Japanese multiinstitutional study［J］. J Thorac Oncol, 2007, 2(7 Suppl 3): S94-S100. ［15］ Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in earlystage NSCLC: doselimiting toxicity in apical tumor sites［J］. Radiother Oncol, 2009, 93(3): 408-413. ［16］ Steven WD, Douglas AR, Ajay PS. Stereotactic body radiation therapy (SBRT) for nonsmall cell lung cancer (NSCLC): current concepts and future directions［J］. Transl Cancer Res, 2014, 3(4): 303-312. ［17］ Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer［J］. JAMA, 2010, 303(11): 1070-1076. ［18］ Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage Ⅰ nonsmallcell lung cancer［J］. J Clin Oncol, 2010, 28(6): 928-935. ［19］ Louie AV, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for medically operable stage Ⅰ nonsmallcell lung cancer: a markov modelbased decision analysis［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4): 964-973.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.

早期非小细胞肺癌的体部立体定向放疗

Stereotactic body radiotherapy for early stage nonsmall cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价